Im Hee-Jin, Kim Jee Hyun, Yun Chang-Ho, Kim Dong Wook, Oh Jeeyoung
Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong 18450, Korea.
Department of Neurology, Ewha Womans University Seoul Hospital, Ewha Womans University School of Medicine, Seoul 07804, Korea.
J Clin Med. 2020 Dec 20;9(12):4115. doi: 10.3390/jcm9124115.
Restless legs syndrome (RLS) is a common sensory motor neurological disorder that is related to iron-dopamine dysregulation and immune system alteration. We aimed to assess the effects of serum hepcidin, an iron-regulating hormone, in drug-naive RLS patients compared to healthy controls and to evaluate its role in helping to predict clinical improvement after treatment with dopamine agonist.
Nonanemic and drug-naive RLS patients ( = 18) and healthy controls ( = 15) were enrolled. The serum hepcidin and iron-related values in the serum were measured upon the first visit in both groups and 12 weeks later after dopaminergic treatment in 12 patients. Information about sociodemographic characteristics, sleep-related profiles, mood and anxiety was obtained upon the first visit in all participants as well as after treatment in RLS patients.
Serum hepcidin levels exhibited no significant differences between patients with drug-naïve RLS and healthy controls at diagnosis (7.1 ± 2.4 vs. 7.0 ± 3.2 ng/mL, = 0.357). Decreased hepcidin levels were significantly associated with decreased RLS severity (β = 0.002, 95% CI = 0.00-0.00, = 0.005) and improved quality of life (β = 0.002, 95% CI = 0.00-7.01, = 0.044) in a dose-dependent manner after 12 weeks of treatment with a dopamine agonist. This association was independent of age, sex, inflammatory markers, sleep quality, insomnia, daytime sleepiness, depression and anxiety.
This study demonstrates the role of hepcidin in evaluating the positive therapeutic response in RLS.
不宁腿综合征（RLS）是一种常见的感觉运动性神经疾病，与铁 - 多巴胺调节异常和免疫系统改变有关。我们旨在评估血清铁调素（一种铁调节激素）在未接受过药物治疗的RLS患者与健康对照者中的作用，并评估其在预测多巴胺激动剂治疗后临床改善情况中的作用。
纳入未患贫血且未接受过药物治疗的RLS患者（n = 18）和健康对照者（n = 15）。两组患者首次就诊时以及12例患者接受多巴胺能治疗12周后，均测量血清铁调素及血清中铁相关指标。在所有参与者首次就诊时以及RLS患者治疗后，获取有关社会人口学特征、睡眠相关情况、情绪和焦虑的信息。
在诊断时，未接受过药物治疗的RLS患者与健康对照者的血清铁调素水平无显著差异（7.1±2.4 vs. 7.0±3.2 ng/mL，P = 0.357）。接受多巴胺激动剂治疗12周后，铁调素水平降低与RLS严重程度降低（β = 0.002，95%CI = 0.00 - 0.00，P = 0.005）和生活质量改善（β = 0.002，95%CI = 0.00 - 7.01，P = 0.044）呈剂量依赖性显著相关。这种关联独立于年龄、性别、炎症标志物、睡眠质量、失眠、日间嗜睡、抑郁和焦虑。
本研究证明了铁调素在评估RLS阳性治疗反应中的作用。
